

Policy: MP266

Section: Medical Benefit Policy

Subject: Magnetoencephalography (MEG) and Magnetic Source Imaging (MSI)

Applicable Lines of Business

Commercial	X	CHIP	X
Medicare	X	ACA	X
Medicaid	X		

I. Policy: Magnetoencephalography (MEG) and Magnetic Source Imaging (MSI)

II. Purpose/Objective:

To provide a policy of coverage regarding Magnetoencephalography (MEG) and Magnetic Source Imaging (MSI)

III. Responsibility:

- A. Medical Directors
- B. Medical Management

IV. Required Definitions

1. Attachment – a supporting document that is developed and maintained by the policy writer or department requiring/authoring the policy.
2. Exhibit – a supporting document developed and maintained in a department other than the department requiring/authoring the policy.
3. Devised – the date the policy was implemented.
4. Revised – the date of every revision to the policy, including typographical and grammatical changes.
5. Reviewed – the date documenting the annual review if the policy has no revisions necessary.

V. Additional Definitions

Medical Necessity or Medically Necessary means Covered Services rendered by a Health Care Provider that the Plan determines are:

- a. appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury;
- b. provided for the diagnosis, and the direct care and treatment of the Member's condition, illness disease or injury;
- c. in accordance with current standards of good medical treatment practiced by the general medical community.
- d. not primarily for the convenience of the Member, or the Member's Health Care Provider; and
- e. the most appropriate source or level of service that can safely be provided to the Member. When applied to hospitalization, this further means that the Member requires acute care as an inpatient due to the nature of the services rendered or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient.

Medicaid Business Segment

Medically Necessary — A service, item, procedure, or level of care that is necessary for the proper treatment or management of an illness, injury, or disability is one that:

- Will, or is reasonably expected to, prevent the onset of an illness, condition, injury or disability.
- Will, or is reasonably expected to, reduce or ameliorate the physical, mental or developmental effects of an

illness, condition, injury or disability.

- Will assist the Member to achieve or maintain maximum functional capacity in performing daily activities, taking into account both the functional capacity of the Member and those functional capacities that are appropriate for Members of the same age

DESCRIPTION:

Magnetoencephalography (MEG) is a noninvasive functional imaging technique that records magnetic fields generated by brain activity. When the information is superimposed on an anatomic image of the brain such as a magnetic resonance imaging scan, the image is referred to as magnetic source imaging (MSI).

INDICATIONS:

Magnetoencephalography (MEG) and Magnetic Source Imaging (MSI) may be considered medically necessary for the following indications:

- Pre-surgical evaluation in patients with intractable focal epilepsy to identify and localize area(s) of epileptiform activity when other techniques designed to localize a focus are discordant or inconclusive; or
- Pre-surgical evaluation in patients with tumors and AVM's located in close proximity to the eloquent cortex

EXCLUSIONS:

MEG or MSI used as a stand-alone test or as the first order of test after clinical and routine electroencephalography (EEG) diagnosis of epilepsy because it is considered **experimental, investigational or unproven** and is **NOT COVERED**.

MEG or MSI used for evaluation of any of the following indications is considered **experimental, investigational or unproven** and is **NOT COVERED**:

- Alzheimer's disease
- Autism
- Learning disorders
- Migraines
- Multiple sclerosis
- Parkinson's disease
- Schizophrenia
- Traumatic Brain Injury

MEG or MSI used for any indication not specifically listed is considered **experimental, investigational or unproven** and is **NOT COVERED**.

Note: A complete description of the process by which a given technology or service is evaluated and determined to be experimental, investigational or unproven is outlined in **MP 15 - Experimental Investigational or Unproven Services or Treatment**

Medicaid Business Segment:

Any requests for services, that do not meet criteria set in the PARP, may be evaluated on a case by case basis.

CODING ASSOCIATED WITH: Magnetoencephalography (MEG) and Magnetic Source Imaging (MSI)
The following codes are included below for informational purposes and may not be all inclusive. Inclusion of a procedure or device code(s) does not constitute or imply coverage nor does it imply or guarantee provider reimbursement. Coverage is determined by the member specific benefit plan document and any applicable laws regarding coverage of specific services.

HCPCS/CPT Codes:

- 95965 Magnetoencephalography (MEG), recording and analysis; for spontaneous brain magnetic activity (e.g., epileptic cerebral cortex localization)
- 95966 Magnetoencephalography (MEG), recording and analysis; for evoked magnetic fields, single modality (e.g., sensory, motor, language, or visual cortex localization)
- 95967 Magnetoencephalography (MEG), recording and analysis; for evoked magnetic fields, each additional modality (e.g., sensory, motor, language, or visual cortex localization)
- S8035 magnetic source imaging

LINE OF BUSINESS:

Eligibility and contract specific benefit limitations and/or exclusions will apply. Coverage statements found in the line of business specific benefit document will supercede this policy. For Medicare, applicable LCD's and NCD's will supercede this policy. For PA Medicaid Business segment, this policy applies as written.

REFERENCES:

Geisinger Technology Assessment Committee Triage Group. June 2012

American Academy of Neurology Professional Association (AANPA). Magnetoencephalography (MEG) Policy. Recommended by the AANPA Medical Economics and Management Committee. Approved by the AANPA Board of Directors on May 8, 2009. St. Paul, MN: AANPA; 2009

Zhang N, Qiao H, Wang YJ, Sun B, Feng YG, Shu N. The application of magnetoencephalography versus scalp electroencephalography in intractable temporal lobe epilepsy. *Zhonghua Nei Ke Za Zhi*. 2007 May;46(5):370-372.

Schneider F, Alexopoulos AV, Wang Z, Almubarak S, Kakisaka Y, Jin K, Nair D, Mosher JC, Najm IM, Burgess RC. Magnetic source imaging in non-lesional neocortical epilepsy: Additional value and comparison with ICEEG. *Epilepsy Behav*. 2012 Apr 27. [Epub ahead of print]

De Tiège X, Carrette E, Legros B, Vonck K, Op de Beeck M, Bourguignon M, Massager N, David P, Van Roost D, Meurs A, Lapere S, Deblaere K, Goldman S, Boon P, Van Bogaert P. Clinical added value of magnetic source imaging in the presurgical evaluation of refractory focal epilepsy. *J Neurol Neurosurg Psychiatry*. 2012 Apr;83(4):417-23

Sutherling WW, Mamelak AN, Thyerlei D, Maleeva T, Minazad Y, Philpott L, Lopez N. Influence of magnetic source imaging for planning intracranial EEG in epilepsy. *Neurology*. 2008 Sep 23;71(13):990-996.

Lau M, Yam D, Burneo JG. A systematic review on MEG and its use in the presurgical evaluation of localization-related epilepsy. *Epilepsy Res*. 2008; 79(2-3):97-104

Ossenblok P, de Munck JC, Colon A, Drolsbach W, Boon P. Magnetoencephalography is more successful for screening and localizing frontal lobe epilepsy than electroencephalography. *Epilepsia*. 2007 Nov;48(11):2139-2149.

Kaiboriboon K, Nagarajan S, Mantle M, Kirsch HE. Interictal MEG/MSI in intractable mesial temporal lobe epilepsy: spike yield and characterization. *Clin Neurophysiol*. 2010 Mar;121(3):325-331.

Korvenoja A, Kirveskari E, Aronen HJ, Avikainen S, Brander A, Huttunen J, Ilmoniemi RJ, Jääskeläinen JE, Kovala T, Mäkelä JP, Salli E, Seppä M. Sensorimotor cortex localization: comparison of magnetoencephalography, functional MR imaging, and intraoperative cortical mapping. *Radiology*. 2006 Oct;241(1):213-222.

Doss RC, Zhang W, Risse GL, Dickens DL. Lateralizing language with magnetic source imaging: validation based on the Wada test. *Epilepsia*. 2009 Oct;50(10):2242-8.

Lewine JD1, Davis JT, Bigler ED, Thoma R, Hill D, Funke M, Sloan JH, Hall S, Orrison WW Objective documentation of traumatic brain injury subsequent to mild head trauma: multimodal brain imaging with MEG, SPECT, and MRI. *J Head Trauma Rehabil*. 2007 May-Jun;22(3):141-55.

Kotini A1, Anninos P, Tamiolakis D. MEG mapping in multiple sclerosis patients. *Eura Medicophys*. 2007 Sep;43(3):345-8.

Tarapore PE1, Martino J, Guggisberg AG, Owen J, Honma SM, Findlay A, Berger MS, Kirsch HE, Nagarajan SS. Magnetoencephalographic imaging of resting-state functional connectivity predicts postsurgical neurological outcome in brain gliomas. *Neurosurgery*. 2012 Nov;71(5):1012-22

Agirre-Arrizubieta Z1, Thai NJ, Valentín A, Furlong PL, Seri S, Selway RP, Elwes RD, Alarcón G The value of Magnetoencephalography to guide electrode implantation in epilepsy. *Brain Topogr*. 2014 Jan;27(1):197-207

Stam CJ. Use of magnetoencephalography (MEG) to study functional brain networks in neurodegenerative disorders. *J Neurol Sci*. 2010 Feb 15;289(1-2):128-34.

Xiang J1, deGrauw X, Korostenskaja M, Korman AM, O'Brien HL, Kabbouche MA, Powers SW, Hershey AD. Altered cortical activation in adolescents with acute migraine: a magnetoencephalography study. *J Pain*. 2013 Dec;14(12):1553-63.

Poza J1, Hornero R, Abásolo D, Fernández A, Mayo A. Evaluation of spectral ratio measures from spontaneous MEG recordings in patients with Alzheimer's disease. *Comput Methods Programs Biomed*. 2008 May;90(2):137-47.

Siekmeier PJ¹, Stufflebeam SM. Patterns of spontaneous magnetoencephalographic activity in patients with schizophrenia. *J Clin Neurophysiol*. 2010 Jun;27(3):179-90

Escudero J¹, Ifeachor E, Fernández A, López-Ibor JJ, Hornero R. Changes in the MEG background activity in patients with positive symptoms of schizophrenia: spectral analysis and impact of age. *Physiol Meas*. 2013 Feb;34(2):265-79

Olde Dubbelink KT¹, Hillebrand A, Stoffers D, Deijen JB, Twisk JW, Stam CJ, Berendse HW. Disrupted brain network topology in Parkinson's disease: a longitudinal magnetoencephalography study. *Brain*. 2014 Jan;137(Pt 1):197-207.

Falco-Walter J, Owen C, Sharma M, et al. Magnetoencephalography and new imaging modalities in epilepsy. *Neurotherapeutics*. 2017;14(1):4-10.

van Straaten EC, de Waal H, Lansbergen MM, et al. Magnetoencephalography for the detection of intervention effects of a specific nutrient combination in patients with mild Alzheimer's disease: Results from an exploratory double-blind, randomized, controlled study. *Front Neurol*. 2016;7:161

Alhourani A, Wozny TA, Krishnaswamy D, et al. Magnetoencephalography-based identification of functional connectivity network disruption following mild traumatic brain injury. *J Neurophysiol*. 2016;116(4):1840-1847

Bagic AI, Bowyer SM, Kirsch HE, et al. American Clinical MEG Society (ACMEGS) Position Statement #2: The value of magnetoencephalography (MEG)/magnetic source imaging (MSI) in noninvasive presurgical mapping of eloquent cortices of patients preparing for surgical interventions. *J Clin Neurophysiol*. May 2017;34(3):189-195.

Harmsen IE, Rowland NC, Wennberg RA, Lozano AM. Characterizing the effects of deep brain stimulation with magnetoencephalography: A review. *Brain Stimul*. 2018 Jan 4

Schmid E, Thomschewski A, Taylor A, et al; E-PILEPSY consortium. Diagnostic accuracy of functional magnetic resonance imaging, Wada test, magnetoencephalography, and functional transcranial Doppler sonography for memory and language outcome after epilepsy surgery: A systematic review. *Epilepsia*. 2018;59(12):2305-2317.

Mouthaan, BB, Rados, MM, Boon, PP. Diagnostic accuracy of interictal source imaging in presurgical epilepsy evaluation: A systematic review from the E-PILEPSY consortium. *Clin Neurophysiol*, 2019 Mar 3;130(5).

Duez L, Tankisi H, Hansen PO, et al. Electromagnetic source imaging in presurgical workup of patients with epilepsy: A prospective study. *Neurology*. 2019;92(6):e576-e586.

Khan H, Sami MB, Litvak V. The utility of magnetoencephalography in multiple sclerosis - A systematic review. *Neuroimage Clin*. 2021;32:102814

Jahed S, Daneshvari NO, Liang AL, et al. Neuroimaging correlates of syndromal anxiety following traumatic brain injury: A systematic review of the literature. *J Acad Consult Liaison Psychiatry*. 2021 Sep 14

Zebhauser PT, Hohn VD, Ploner M. Resting-state electroencephalography and magnetoencephalography as biomarkers of chronic pain: A systematic review. *Pain*. 2023;164(6):1200-1221.

Das S, Zomorodi R, Mirjalili M, et al. Machine learning approaches for electroencephalography and magnetoencephalography analyses in autism spectrum disorder: A systematic review. *Prog Neuropsychopharmacol Biol Psychiatry*. 2023;123:110705.

This policy will be revised as necessary and reviewed no less than annually.

Devised: 7/2/2012

Revised: 7/14 (added exclusions)

Reviewed: 7/13, 7/15, 7/16, 6/17, 6/18, 6/19, 6/20, 6/21, 6/22, 6/23, 6/24

CMS UM Oversight Committee Approval: 12/23, 7/24

Geisinger Health Plan may refer collectively to health care coverage sponsors Geisinger Health Plan, Geisinger Quality Options, Inc., and Geisinger Indemnity Insurance Company, unless otherwise noted. Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

Coverage for experimental or investigational treatments, services and procedures is specifically excluded under the member's certificate with Geisinger Health Plan. Unproven services outside of an approved clinical trial are also specifically excluded under the member's certificate with Geisinger Health Plan. This policy does not expand coverage to services or items specifically excluded from coverage in the member's certificate with Geisinger Health Plan. Additional information can be found in MP015 Experimental, Investigational or Unproven Services.

Prior authorization and/or pre-certification requirements for services or items may apply. Pre-certification lists may be found in the member's contract specific benefit document. Prior authorization requirements can be found at <https://www.geisinger.org/health-plan/providers/ghp-clinical-policies>

Please be advised that the use of the logos, service marks or names of Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company on a marketing, press releases or any communication piece regarding the contents of this medical policy is strictly prohibited without the prior written consent of Geisinger Health Plan. Additionally, the above medical policy does not confer any endorsement by Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company regarding the medical service, medical device or medical lab test described under this medical policy.